Kiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Earnings Results, Misses Estimates By $0.06 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) released its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), Zacks reports. The firm had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s quarterly revenue was up 46.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.35 EPS.

Kiniksa Pharmaceuticals Trading Up 1.3 %

Shares of KNSA stock traded up $0.26 on Thursday, hitting $19.95. 81,525 shares of the stock were exchanged, compared to its average volume of 556,799. The firm has a market capitalization of $1.44 billion, a P/E ratio of -142.49 and a beta of 0.32. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15. The business has a 50-day moving average of $19.68 and a 200 day moving average of $22.57.

Insider Activity at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at $492,449.10. The trade was a 28.09 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,092 shares of company stock valued at $745,589. 54.57% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on KNSA shares. JPMorgan Chase & Co. increased their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday. Finally, Evercore ISI lifted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.